Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents

This publication has 89 references indexed in Scilit:

• A Catalytic Role for Proangiogenic Marrow-Derived Cells in Tumor Neovascularization
  Cancer Cell, 2008
• Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
  Proceedings of the National Academy of Sciences, 2007
• PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
  British Journal of Cancer, 2007
• Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
  Published by Elsevier ,2007
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
  British Journal of Cancer, 2007
• AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
  Cancer Cell, 2007
• Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
  New England Journal of Medicine, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004